3 Diabetes Biotechs That Could Surge 50% or More in 2018 Post author:Sam Post published:January 21, 2018 Post category:BioPharma Wall Street projects these three biotechs will grow the fastest over the next 12 months. Source: BioSpace You Might Also Like Why This Pharma Surged After Trump's Opioid Declaration October 26, 2017 Celyad Grants To Novartis AG A Non-Exclusive License For Its Allogeneic TCR-Deficient CAR-T Cells Patents May 1, 2017 FDA Rejects Johnson & Johnson's RA Drug Sirukumab, More Safety Data Needed September 24, 2017
Celyad Grants To Novartis AG A Non-Exclusive License For Its Allogeneic TCR-Deficient CAR-T Cells Patents May 1, 2017
